Dr. Gill reviews the advantages and challenges of using the newly approved recombinant von WIllebrand factor replacement product in clinical practice.
Joan C. Gill, MD: New Recombinant Factors for von Willebrand Disease
Recent Articles
Trump Administration Ends Fetal Tissue Research at NIH
In the latest in a string of decisions pleasing to anti-abortion groups, the Trump administration announced sharp cuts to federal spending on fetal-tissue research,...
Gene Modified in Chinese “CRISPR Babies” Associated with Premature Death
A new study in Nature Medicine indicates that the gene that He Jiankui, PhD, modified in twin baby girls to mitigate HIV risk in...
Insys Therapeutics to Pay $225 Million Settlement For Its Role in the Opioid Crisis
Drugmaker Insys Therapeutics has admitted to bribing physicians to prescribe fentanyl sublingual – its opioid painkiller – and will pay a $225 million settlement...
Health Care Worker Shortages Loom as Boomers Age and Policies Curtailing
According to a new study published in Health Affairs, immigrants (both citizens and non-citizens) make up a disproportionate share of workers caring for the...
Bluebird Bio Wins European Approval for First Beta Thalassemia Gene Therapy
Bluebird Bio’s one-time gene therapy, Zynteglo, has been cleared by EU regulators for the treatment of beta thalassemia in patients aged 12 and older....
Current Issue
June 2019, Volume 5, Issue 7
This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.
